News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
62,707 Results
Type
Article (5103)
Company Profile (28)
Press Release (57574)
Multimedia
Podcasts (4)
Webinars (4)
Section
Business (18864)
Career Advice (266)
Deals (3031)
Drug Delivery (11)
Drug Development (3642)
Employer Resources (23)
FDA (1251)
Job Trends (1775)
News (27149)
Policy (2263)
Tag
Academia (580)
Accelerated approval (1)
Allergies (5)
Alliances (6266)
ALS (13)
Alzheimer's disease (140)
Antibody-drug conjugate (ADC) (28)
Approvals (1273)
Artificial intelligence (130)
Autoimmune disease (13)
Automation (22)
Bankruptcy (31)
Best Places to Work (1224)
BIOSECURE Act (1)
Biosimilars (26)
Biotechnology (14)
Bladder cancer (3)
Brain cancer (6)
Breast cancer (42)
Cancer (366)
Cardiovascular disease (36)
Career advice (237)
Career pathing (12)
CAR-T (17)
CDC (2)
Cell therapy (54)
Cervical cancer (11)
Clinical research (2671)
Collaboration (248)
Compensation (25)
Complete response letters (1)
COVID-19 (436)
CRISPR (13)
C-suite (71)
Cystic fibrosis (9)
Data (374)
Denatured (1)
Depression (20)
Diabetes (18)
Diagnostics (1871)
Digital health (7)
Diversity (1)
Diversity, equity & inclusion (3)
Drug discovery (49)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (3)
Earnings (5256)
Editorial (5)
Employer branding (2)
Employer resources (21)
Events (7006)
Executive appointments (99)
FDA (1453)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (200)
Gene editing (22)
Generative AI (10)
Gene therapy (43)
GLP-1 (62)
Government (482)
Grass and pollen (1)
Guidances (27)
Healthcare (1717)
HIV (6)
Huntington's disease (3)
IgA nephropathy (2)
Immunology and inflammation (16)
Immuno-oncology (4)
Indications (3)
Infectious disease (474)
Inflammatory bowel disease (16)
Influenza (34)
Intellectual property (12)
Interviews (34)
IPO (1113)
IRA (4)
Job creations (545)
Job search strategy (201)
JPM (11)
Labor market (20)
Layoffs (45)
Leadership (15)
Legal (384)
Liver cancer (3)
Longevity (3)
Lung cancer (35)
Lymphoma (25)
Machine learning (15)
Management (5)
Manufacturing (109)
MASH (2)
Medical device (1187)
Medtech (1192)
Mergers & acquisitions (2035)
Metabolic disorders (50)
Multiple sclerosis (6)
Neurodegenerative disease (24)
Neuropsychiatric disorders (9)
Neuroscience (256)
Neurotech (1)
NextGen: Class of 2026 (753)
Non-profit (581)
Now hiring (19)
Obesity (29)
Opinion (55)
Ovarian cancer (10)
Pain (12)
Pancreatic cancer (15)
Parkinson's disease (26)
Partnered (9)
Patents (23)
Patient recruitment (18)
Peanut (4)
People (5460)
Pharmaceutical (4)
Phase 1 (913)
Phase 2 (1189)
Phase 3 (903)
Pipeline (475)
Policy (14)
Postmarket research (98)
Preclinical (598)
Press Release (18)
Prostate cancer (21)
Psychedelics (7)
Radiopharmaceuticals (13)
Rare diseases (41)
Real estate (1481)
Recruiting (13)
Regulatory (1682)
Reports (11)
Research institute (546)
Resumes & cover letters (31)
Rett syndrome (3)
RNA editing (1)
RSV (6)
Schizophrenia (15)
Series A (40)
Series B (22)
Service/supplier (2)
Sickle cell disease (2)
Special edition (3)
Spinal muscular atrophy (5)
Sponsored (8)
Startups (587)
Stomach cancer (1)
Supply chain (11)
Tariffs (4)
The Weekly (3)
Vaccines (44)
Venture capital (19)
Weight loss (15)
Women's health (11)
Worklife (5)
Date
Today (5)
Last 7 days (46)
Last 30 days (178)
Last 365 days (2439)
2026 (240)
2025 (2468)
2024 (3089)
2023 (3709)
2022 (5164)
2021 (5411)
2020 (5978)
2019 (4605)
2018 (3294)
2017 (3166)
2016 (3400)
2015 (3466)
2014 (2391)
2013 (2134)
2012 (2318)
2011 (2458)
2010 (1878)
Location
Africa (114)
Alabama (10)
Alaska (1)
Arizona (28)
Arkansas (1)
Asia (3401)
Australia (445)
California (1193)
Canada (238)
China (78)
Colorado (38)
Connecticut (95)
Delaware (15)
Europe (6767)
Florida (62)
Georgia (26)
Idaho (5)
Illinois (59)
India (13)
Indiana (64)
Iowa (9)
Japan (27)
Kansas (6)
Kentucky (3)
Louisiana (3)
Maine (6)
Maryland (94)
Massachusetts (574)
Michigan (89)
Minnesota (46)
Mississippi (1)
Missouri (30)
Montana (4)
Nebraska (8)
Nevada (10)
New Hampshire (9)
New Jersey (176)
New Mexico (11)
New York (240)
North Carolina (132)
North Dakota (3)
Northern California (650)
Ohio (65)
Oklahoma (3)
Oregon (10)
Pennsylvania (162)
Rhode Island (5)
South America (200)
South Carolina (8)
Southern California (289)
Tennessee (41)
Texas (138)
United States (3438)
Utah (54)
Virginia (21)
Washington D.C. (6)
Washington State (79)
West Virginia (2)
Wisconsin (23)
62,707 Results for "altos labs".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
January 15, 2026
·
5 min read
Press Releases
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
January 13, 2026
·
5 min read
Press Releases
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
February 4, 2026
·
4 min read
Press Releases
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
October 6, 2025
·
5 min read
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to signals of drug activity, William Blair said, though the analysts pointed to other indications as potentially more promising for future development.
June 27, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
October 21, 2025
·
7 min read
Press Releases
Alto Neuroscience to Participate in Upcoming November 2025 Investor Conferences
October 29, 2025
·
1 min read
Press Releases
Alto Neuroscience Announces $50 Million Private Placement Financing
October 21, 2025
·
6 min read
Press Releases
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
November 13, 2025
·
12 min read
Press Releases
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - December 3, 2025
December 4, 2025
·
1 min read
1 of 6,271
Next
